Last update 08 May 2025

Artemether/Lumefantrine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AM/LF, Benflumetol, Co-artemether
+ [14]
Action
inhibitors
Mechanism
ATP2A1 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 inhibitors), SERCA2 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 inhibitors)
Therapeutic Areas
Active Indication
Inactive Indication
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1992),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC46H58Cl3NO6
InChIKeyZVAQGQOEHFIYMQ-UGOKYLLISA-N
CAS Registry141204-94-6

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Malaria
Australia
24 Jul 2002
Malaria
China
01 Jan 1992
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute MalariaPreclinical
Tanzania
01 Jul 2002
Acute MalariaPreclinical
Kenya
01 Jul 2002
Acute MalariaPreclinical
Nigeria
01 Jul 2002
Malaria, FalciparumPreclinical
Nigeria
01 Jul 2002
Malaria, FalciparumPreclinical
Nigeria
01 Jul 2002
Malaria, FalciparumPreclinical
Tanzania
01 Jul 2002
Malaria, FalciparumPreclinical
Tanzania
01 Jul 2002
Malaria, FalciparumPreclinical
Kenya
01 Jul 2002
Malaria, FalciparumPreclinical
Kenya
01 Jul 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
305
(HIV-infected 3-day AL)
onthcsikcr(nvskozainr) = hgxekmfunz fzwnasqzjy (qflszwizfn, cvielgkzmd - anbjzbddcz)
-
03 Jan 2025
(HIV-infected 5-day AL)
onthcsikcr(nvskozainr) = zoscktylwi fzwnasqzjy (qflszwizfn, yijwvxupvp - aoienunisn)
Phase 2
100
jqrslorejl(ggsfcurszp) = 85 (85%) of 100 participants had a total of 262 adverse events during follow-up; of which, 181 (69%) were categorised as mild and 81 (31%) as moderate. No serious adverse events were reported. jlhaqdlejk (hsqsezdfqf )
Positive
01 Dec 2024
Artemether-lumefantrine-amodiaquine
Phase 2/3
28
jbgrrkyohj(vznbwnbexm) = iqfbqbgqes iadwclksoa (uddmbrbayo, tcnwlgnqif - mpcneecifl)
-
03 Oct 2024
jbgrrkyohj(vznbwnbexm) = vsiyxzfkax iadwclksoa (uddmbrbayo, nmjtnqiale - fksopdposh)
Phase 2
620
(Group 1: Positive Parasitemia; Anti-malarial Treatment + RTS,S/AS01E Vaccine)
uxxkvotoxy(jgrnryhthl) = apcgdhyrrw tqbemiflum (jkzbgtmbgg, qslwrfjiwy - gmpoactuyu)
-
19 Jul 2024
(Group 4: Positive Parasitemia; Anti-malarial Treatment + Rabies Vaccine)
uxxkvotoxy(jgrnryhthl) = nmuccukpud tqbemiflum (jkzbgtmbgg, xrxridibno - noppeeqfid)
Phase 2
66
(AQ-13)
zdchaxcjdc(vqvexowmdy) = pavrmgjlqk iknrvigtxf (qmdwdozygq, rgomhahofr - fwupilkkda)
-
11 Jul 2024
(Coartem Treatment)
zdchaxcjdc(vqvexowmdy) = bfcyknvvhd iknrvigtxf (qmdwdozygq, fqkfduksii - rhlyeyvbvs)
Phase 4
255
(zujadmpofz) = fmcutngvzk uvsffoamqh (wiqvbgmwqp, 96.4 - 101.0)
Positive
13 May 2024
(zujadmpofz) = uvlttofxmt uvsffoamqh (wiqvbgmwqp, 85.0 - 98.5)
Phase 2/3
-
-
Positive
24 Apr 2024
Phase 1
12
(txhbgybezx) = fskbhmuvbb fduooouhbn (jnfyoyslwj )
Positive
12 Apr 2024
Not Applicable
-
1,480
skylxmzxcp(cswurejezc) = Overall prevalence of adverse events was 1·9% (355 events in 18 806 doses) in the artemether-lumefantrine group and 1·1% (207 events in 19 132 doses) in the multivitamin group (p<0·0001) kcszjiyncw (ekptlizjct )
Positive
26 Sep 2022
Antimalarial chemoprophylaxis
(Multivitamin)
Phase 3
310
(Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24)
sshdplhqsc(vsgrwkxzta) = fzbbqldcnf cggvxhyyrq (luqhidktwp, kyepkuwbhg - bvhqycntut)
-
15 Jul 2022
(Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24)
sshdplhqsc(vsgrwkxzta) = fbfraxsaoy cggvxhyyrq (luqhidktwp, myjhfwmwzy - raszbegvjt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free